Shares of Voyager Therapeutics dropped more than 12% before the opening bell this morning as investors are reacting negatively to an announcement that Neurocrine Biosciences is terminating a Parkinson’s disease collaboration between the two companies.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,